Abiopharma

New Form 4 - ARVINAS, INC. Filed: 2025-06-30 AccNo: 0001655759-25-000126 Size: 7 KB

New Form DEFM14A - Vigil Neuroscience, Inc. Filed: 2025-06-30 AccNo: 0001193125-25-151902 Size: 1 MB

New Form 6-K - TAKEDA PHARMACEUTICAL CO LTD Filed: 2025-06-30 AccNo: 0001395064-25-000105 Size: 10 MB

New Form 8-K - Fortive Corp Filed: 2025-06-30 AccNo: 0001659166-25-000104 Size: 2 MB Item 1.01: Entry into a Material Definitive Agreement Item 2.01: Completion of Acquisition or Disposition of Assets Item 2.02: Results of Operations and Financial Condition Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment …

New Form 6-K - Addex Therapeutics Ltd. Filed: 2025-06-30 AccNo: 0001171843-25-004208 Size: 15 KB

New Form 8-K - Aurinia Pharmaceuticals Inc. Filed: 2025-06-30 AccNo: 0001600620-25-000083 Size: 2 MB Item 8.01: Other Events

New Form EFFECT - Bone Biologics Corp Filed: 2025-06-27 AccNo: 9999999995-25-002071 Size: 2 KB

New Form EFFECT - Jaguar Health, Inc. Filed: 2025-06-27 AccNo: 9999999995-25-002069 Size: 1 KB

New Form EFFECT - Inhibikase Therapeutics, Inc. Filed: 2025-06-27 AccNo: 9999999995-25-002070 Size: 1 KB

New Form EFFECT - RetinalGenix Technologies Inc. Filed: 2025-06-27 AccNo: 9999999995-25-002047 Size: 1 KB

New Form EFFECT - RetinalGenix Technologies Inc. Filed: 2025-06-27 AccNo: 9999999995-25-002048 Size: 1 KB

Aurinia Announces Positive Results from Phase 1 Study of Aritinercept (AUR200)

Fortive Announces Completion of the Ralliant Separation and Appointment of Olumide Soroye as President, CEO and Director of Fortive

General Announcement: EXERCISE PRICE OF SGD0.38 PER WARRANT FOR WARRANTS LISTED ON SGX-ST FROM 01/07/2025 UNTIL 30/09/2025

General Announcement: CHANGES IN SUBSTANTIAL SHAREHOLDERS INTEREST PURSUANT TO SECTION 138 OF THE COMPANIES ACT 2016